FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311013507> ?p ?o ?g. }

• W4311013507 endingPage "6" @default.
• W4311013507 startingPage "1" @default.
• W4311013507 abstract "Background. An in-silico screen identified mebendazole with potential antiviral activity that could be a repurposed drug against SARS-CoV-2. Mebendazole is a well-tolerated and cheap antihelminthic agent that is readily available worldwide and thus could be a therapeutic tool in the fight against COVID-19. Methods. This is an observational retrospective study of PCR-confirmed COVID-19 patients who received mebendazole with the intention-to-treat. The study included an inpatient cohort (157 inpatients) and an outpatient cohort (185 outpatients). Of the 157 inpatients and 185 outpatients, 68 (43.3%) and 94 (50.8%) received mebendazole, respectively. Patients who presented within the same timeframe but did not receive mebendazole were used as controls. Patients received standard-of-care treatment including remdesivir, dexamethasone, and anticoagulants as deemed necessary by the treating physician. The following clinical outcomes were evaluated: for the inpatient cohort, length of stay (LOS) at the hospital, need for ventilation (combined invasive and noninvasive), and mortality; for the outpatient cohort, time to symptom resolution, need for hospitalization, and mortality. Results. For the inpatient cohort, the median age did not differ between the treatment and control groups; 62 (56, 67) vs. 62 (56, 68), <math xmlns=http://www.w3.org/1998/Math/MathML id=M1> <mi>P</mi> </math> , and there was a comparable proportion of males in both groups; 43 (63%) vs. 55 (62%), <math xmlns=http://www.w3.org/1998/Math/MathML id=M2> <mi>P</mi> <mo>=</mo> <mn>0.85</mn> </math> . The hospital LOS was 3.5 days shorter in the treatment group compared to the control group ( <math xmlns=http://www.w3.org/1998/Math/MathML id=M3> <mi>P</mi> <mo><</mo> <mn>0.001</mn> </math> ). There were fewer patients who required invasive or noninvasive ventilation in the treatment group, 2 (2.9%) vs. 7 (7.9%), and the mortality rate is lower in the treatment group, 3 (4.4%) vs. 8 (9.0%), though the differences did not reach statistical significance. For the outpatient cohort, the median age was lower in the treatment group compared with the control group; 40 (34, 48) vs. 48 (41, 54), <math xmlns=http://www.w3.org/1998/Math/MathML id=M4> <mi>P</mi> <mo><</mo> <mn>0.001</mn> </math> . There was a comparable proportion of males between both groups; 50 (53%) vs. 52 (57%), <math xmlns=http://www.w3.org/1998/Math/MathML id=M5> <mi>P</mi> <mo>=</mo> <mn>0.59</mn> </math> . Patients in the treatment group were 3.3 days closer to symptom resolution ( <math xmlns=http://www.w3.org/1998/Math/MathML id=M6> <mi>P</mi> <mo><</mo> <mn>0.001</mn> </math> ). There were numerically fewer patients requiring hospitalization in the treatment group compared with the control group, 3 (3.2%) vs. 6 (6.6%), though this did not reach statistical significance ( <math xmlns=http://www.w3.org/1998/Math/MathML id=M7> <mi>P</mi> <mo>=</mo> <mn>0.33</mn> </math> ). Conclusion. In this retrospective observational study, the use of mebendazole in COVID-19 patients was associated with shorter hospitalizations in the inpatient cohort and shorter durations of symptom resolution in the outpatient cohort. The findings from this small observational study are hypothesis-generating and preclude drawing conclusions about clinical efficacy. Further studies are needed to examine the role of mebendazole in the treatment of COVID-19 patients." @default.
• W4311013507 created "2022-12-22" @default.
• W4311013507 creator A5014018240 @default.
• W4311013507 creator A5023840226 @default.
• W4311013507 creator A5026434142 @default.
• W4311013507 creator A5051095385 @default.
• W4311013507 creator A5054187099 @default.
• W4311013507 creator A5055891349 @default.
• W4311013507 creator A5058734068 @default.
• W4311013507 creator A5058873172 @default.
• W4311013507 creator A5064968046 @default.
• W4311013507 creator A5082137209 @default.
• W4311013507 creator A5082214306 @default.
• W4311013507 date "2022-12-10" @default.
• W4311013507 modified "2023-10-14" @default.
• W4311013507 title "The Use of Mebendazole in COVID-19 Patients: An Observational Retrospective Single Center Study" @default.
• W4311013507 cites W2041525960 @default.
• W4311013507 cites W2076991654 @default.
• W4311013507 cites W2152173141 @default.
• W4311013507 cites W2268501706 @default.
• W4311013507 cites W2849922468 @default.
• W4311013507 cites W2960610849 @default.
• W4311013507 cites W2971269332 @default.
• W4311013507 cites W3003217347 @default.
• W4311013507 cites W3004280078 @default.
• W4311013507 cites W3004789303 @default.
• W4311013507 cites W3010673910 @default.
• W4311013507 cites W3014962324 @default.
• W4311013507 cites W3037437442 @default.
• W4311013507 cites W3110209099 @default.
• W4311013507 cites W3138775655 @default.
• W4311013507 cites W3154750958 @default.
• W4311013507 cites W3169222793 @default.
• W4311013507 cites W3169782252 @default.
• W4311013507 cites W3176333152 @default.
• W4311013507 cites W3189646261 @default.
• W4311013507 cites W3214271933 @default.
• W4311013507 doi "https://doi.org/10.1155/2022/3014686" @default.
• W4311013507 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36536779" @default.
• W4311013507 hasPublicationYear "2022" @default.
• W4311013507 type Work @default.
• W4311013507 citedByCount "1" @default.
• W4311013507 countsByYear W43110135072023 @default.
• W4311013507 crossrefType "journal-article" @default.
• W4311013507 hasAuthorship W4311013507A5014018240 @default.
• W4311013507 hasAuthorship W4311013507A5023840226 @default.
• W4311013507 hasAuthorship W4311013507A5026434142 @default.
• W4311013507 hasAuthorship W4311013507A5051095385 @default.
• W4311013507 hasAuthorship W4311013507A5054187099 @default.
• W4311013507 hasAuthorship W4311013507A5055891349 @default.
• W4311013507 hasAuthorship W4311013507A5058734068 @default.
• W4311013507 hasAuthorship W4311013507A5058873172 @default.
• W4311013507 hasAuthorship W4311013507A5064968046 @default.
• W4311013507 hasAuthorship W4311013507A5082137209 @default.
• W4311013507 hasAuthorship W4311013507A5082214306 @default.
• W4311013507 hasBestOaLocation W43110135071 @default.
• W4311013507 hasConcept C126322002 @default.
• W4311013507 hasConcept C167135981 @default.
• W4311013507 hasConcept C18903297 @default.
• W4311013507 hasConcept C194828623 @default.
• W4311013507 hasConcept C201903717 @default.
• W4311013507 hasConcept C23131810 @default.
• W4311013507 hasConcept C2779061029 @default.
• W4311013507 hasConcept C71924100 @default.
• W4311013507 hasConcept C72563966 @default.
• W4311013507 hasConcept C86803240 @default.
• W4311013507 hasConceptScore W4311013507C126322002 @default.
• W4311013507 hasConceptScore W4311013507C167135981 @default.
• W4311013507 hasConceptScore W4311013507C18903297 @default.
• W4311013507 hasConceptScore W4311013507C194828623 @default.
• W4311013507 hasConceptScore W4311013507C201903717 @default.
• W4311013507 hasConceptScore W4311013507C23131810 @default.
• W4311013507 hasConceptScore W4311013507C2779061029 @default.
• W4311013507 hasConceptScore W4311013507C71924100 @default.
• W4311013507 hasConceptScore W4311013507C72563966 @default.
• W4311013507 hasConceptScore W4311013507C86803240 @default.
• W4311013507 hasLocation W43110135071 @default.
• W4311013507 hasLocation W43110135072 @default.
• W4311013507 hasLocation W43110135073 @default.
• W4311013507 hasLocation W43110135074 @default.
• W4311013507 hasOpenAccess W4311013507 @default.
• W4311013507 hasPrimaryLocation W43110135071 @default.
• W4311013507 hasRelatedWork W1937161868 @default.
• W4311013507 hasRelatedWork W1971557041 @default.
• W4311013507 hasRelatedWork W2005712411 @default.
• W4311013507 hasRelatedWork W2157077459 @default.
• W4311013507 hasRelatedWork W2754539770 @default.
• W4311013507 hasRelatedWork W2937211356 @default.
• W4311013507 hasRelatedWork W3040911544 @default.
• W4311013507 hasRelatedWork W4210921993 @default.
• W4311013507 hasRelatedWork W4312780918 @default.
• W4311013507 hasRelatedWork W45151993 @default.
• W4311013507 hasVolume "2022" @default.
• W4311013507 isParatext "false" @default.
• W4311013507 isRetracted "false" @default.
• W4311013507 workType "article" @default.